Evidence map›Paper›PMID 41254216›Full record

ArticleNature chemical biology2026

Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap.

Zhi Lin, Wayne Ngo, Yu-Ting Chou, Harry Wu, Katherine J Susa, Young-Wook Jun, Trever G Bivona, Jennifer A Doudna, James A Wells

Abstract read
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Chemical Biology 2025: Highlights From the Ch/Bi145 Course at Caltech.Chembiochem : a European journal of chemical biology · 2026
    Review
  4. Review
  5. Review
  6. AbioRxiv : the preprint server for biology · 2026
    Article
  7. A unified photosensitizer platform forbioRxiv : the preprint server for biology · 2026
    Article
  8. Pausing for stress.Nature chemical biology · 2026
    Article
  9. Tracing the mark of arginine.Nature chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhi LinDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6662-7330
Wayne NgoInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0002-5755-2303
Yu-Ting ChouDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Harry WuDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9745-3839
Katherine J SusaDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Young-Wook JunDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3182-5366
Trever G BivonaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5734-4128
Jennifer A DoudnaInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID 0000-0001-9161-999X
James A WellsDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA. jim.wells@ucsf.edu.ORCID 0000-0001-8267-5519

Funding

UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALVIN J KUO · 2017 to 2026
$12.9M
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
The Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2M
Characterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7M
Spatiotemporal interrogation of molecular mechanobiololgy at the cell-cell interface with nanotechnology toolsR35GM134948 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Young-wook Jun · 2020 to 2026
$3.6M
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targetsR01CA248323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2020 to 2026
$2.6M
Optimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8M
Identifying, Characterizing, and Targeting Regulators of B Cell ActivationDP5OD036136 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine Julia Susa · 2023 to 2026
$1.6M
Targeted Delivery of Cas9 to Lung Epithelial Cells using Enveloped Delivery VehiclesR21HL173710 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI DOUDNA, JENNIFER A · 2024 to 2025
$520k
NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS R01 CA248323NCI NIH HHS U01 CA217882NCI NIH HHS U54 CA224081NHLBI NIH HHS R21 HL173710NIGMS NIH HHS R35 GM122451NIGMS NIH HHS R35 GM134948NIH HHS DP5 OD036136
6 · The paper itself

Abstract

Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both outside and inside of cells. We achieved this by augmenting the multiscale PLP workflow we call MultiMap, where three photoprobes with different labeling ranges were photoactivated by one photocatalyst, eosin Y, anchored extracellularly and intracellularly on EGFR. We identified hundreds of neighboring proteins that changed within minutes to over 1 h after the addition of EGF. These neighborhoods reveal dynamic interactomes during early, middle and late signaling that drive phosphorylation, internalization, degradation and transcriptional regulation. This rapid 'molecular photographic' labeling approach provides snapshots of signaling neighborhoods, revealing their dynamic nature and potential for drug targeting.

Indexed as

ErbB ReceptorsProteomicsStaining and LabelingEpidermal Growth FactorHumansLigandsPhosphorylationSignal TransductionEGFR protein, humanEpidermal Growth FactorErbB ReceptorsLigands

Identifiers

PMID41254216
PMCPMC12858401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.